Skip to Content

Table 41: Antibiotics - Topical


A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z


Drug Category: Dermatological

Medication Class/Individual Agents: Antibiotics

I. Prior-Authorization Requirements

 Topical Antibacterials

Clinical Notes

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

bacitracin test   *, A90
bacitracin / polymyxin B topical ointment double antibiotic ointment test   *, A90
chlorhexidine gluconate test   *, A90
gentamicin topical cream, ointment test   A90
hydrogen peroxide test   *, A90
iodine test   *, A90
isopropyl alcohol test   *, A90
mafenide Sulfamylon test   # , A90
mupirocin cream PA   A90
mupirocin ointment Centany test   A90
mupirocin ointment test   A90
mupirocin powder PA  
neomycin / bacitracin / polymyxin B / hydrocortisone topical ointment Cortisporin test  
neomycin / bacitracin / polymyxin B topical ointment triple antibiotic ointment test   *, A90
neomycin / polymyxin B / hydrocortisone cream Cortisporin test  
ozenoxacin Xepi PA  
povidone test   *, A90
silver sulfadiazine-Silvadene Silvadene test   # , A90
silver sulfadiazine-SSD SSD test   # , A90
silver sulfadiazine-Thermazene Thermazene test   # , A90

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

 

Warnings and Precautions:

  • Contact with eyes should be avoided.
  • Contact with mucosal surfaces should be avoided with mupirocin 2% ointment.
  • If severe local irritation occurs, product should be discontinued.
  • Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi.
  • Mupirocin 2% ointment contains polyethylene glycol. This product should be avoided if large quantities of polyethylene glycol could potentially be absorbed, especially in those with moderate-to-severe renal impairment or open wounds with damaged skin (other formulations do not contain polyethylene glycol).
 

 Vaginal Antibiotics

Drug Details

Drug Generic Name

Drug Brand Name

PA
Status

Drug
Notes

clindamycin vaginal cream-Cleocin Cleocin test   # , A90
clindamycin vaginal cream-Clindesse Clindesse PA  
clindamycin vaginal suppository Cleocin Vaginal Ovule test  
metronidazole 0.75% vaginal gel-Metrogel-Vaginal Metrogel-Vaginal test   # , A90
metronidazole 0.75% vaginal gel-Vandazole Vandazole test   A90
metronidazole 1.3% vaginal gel Nuvessa test  
Table Footnotes
# This designates a brand-name drug with FDA “A”-rated generic equivalents. Prior authorization is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent.
 
* The generic OTC and, if any, generic prescription versions of the drug are payable under MassHealth without prior authorization.
 
A90 Allowable 90-day supply. Dispensing in up to a 90-day supply is allowed. May not include all strengths or formulations. Quantity limits and other restrictions may apply.
 

II. Therapeutic Uses

FDA-approved, for example:

  • Bacterial vaginosis - Clindesse
  • Treatment of impetigo - mupirocin cream, Xepi
  • Infected traumatic lesions - mupirocin cream

Note: The above list may not include all FDA-approved indications.

Back to top


III.  Evaluation Criteria for Approval

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.
  • All PA requests must include clinical diagnosis, drug name, dose, and frequency.
  • Dispensing in a 90-day supply of medication may be mandated or allowable for agents in this therapeutic class (designated by M90 or A90, respectively, in the Drug Notes section above). Applicable quantity limits are described below as units per day, per month, per 28 days, or as clinically appropriate, and may be extrapolated for fills of longer day supply. 
  • A preferred drug may be designated for this therapeutic class. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class. Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.
  • For recertification requests, approval may require submission of additional documentation including, but not limited to, documentation of: some or all criteria for the original approval; response to therapy; clinical rationale for continuation of use; status of member’s condition; appropriate diagnosis; appropriate age; appropriate dose, frequency, and duration of use for requested medication; complete treatment plan; current laboratory values; and member’s current weight.
  • Additional criteria may apply, depending upon the member’s condition and requested medication (see below).

 

Clindesse

  • Documentation of the following is required:
    • an appropriate diagnosis; and
    • an inadequate response, adverse reaction, or contraindication to oral metronidazole tablets or metronidazole vaginal gel; and
    • an inadequate response or adverse reaction to clindamycin vaginal cream or Cleocin Vaginal Ovule; and
    • appropriate dosing.

 

mupirocin cream for impetigo or infected traumatic lesions

  • Documentation of the following is required: 
    • an appropriate diagnosis; and
    • medical records documenting an inadequate response, adverse reaction, or contraindication to mupirocin ointment; and
    • requested quantity is ≤ one package/30 days.

 

mupirocin powder

  • Documentation of all the following is required:
    • appropriate diagnosis; and
    • clinical rationale why other commercially available alternatives cannot be used. 

 

Xepi

  • Documentation of the following is required:
    • an appropriate diagnosis; and
    • member is ≥ two months of age; and
    • one of the following:
      • medical records documenting an inadequate response or adverse reaction to mupirocin cream or mupirocin ointment; or
      • medical records documenting a contraindication to mupirocin cream and mupirocin ointment; and
    • requested quantity is ≤ one package/30 days.


Original Effective Date: 07/2005

Last Revised Date: 09/2022


Clinical Criteria Main Page | Back to topPrevious  |  Next

Last updated 10/31/22

Feedback